Quick Answer: Ozempic, Wegovy, and Mounjaro are all GLP-1-based medications, but they are not identical. Ozempic (semaglutide) is approved in Canada for type 2 diabetes, Wegovy (also semaglutide) is approved specifically for weight management, and Mounjaro (tirzepatide) targets both GLP-1 and GIP receptors and is approved for type 2 diabetes. For weight loss, Wegovy and Mounjaro generally show the strongest results, but the right choice depends on your health history, your goals, and your doctor’s recommendation.
Before comparing them, it helps to understand what each medication actually is. All three belong to a class of drugs that work on hormones involved in appetite and blood sugar, but they differ in their active ingredients and how they work.
Ozempic is a GLP-1 receptor agonist. Its active ingredient is semaglutide, a synthetic version of a natural hormone called glucagon-like peptide-1. GLP-1 helps regulate blood sugar, slows the emptying of your stomach, and signals your brain that you are full.
In Canada, Health Canada has approved Ozempic to treat type 2 diabetes. It is not officially approved for weight loss, although many doctors prescribe it off-label for that purpose because of its strong appetite-suppressing effects.
Wegovy is also semaglutide, the exact same active ingredient as Ozempic. The difference is the dose and the approval. Wegovy is approved by Health Canada specifically for weight management in adults with obesity or overweight who have at least one weight-related condition.
Wegovy is available in higher doses than Ozempic, which is part of why it tends to produce more significant weight loss. It is essentially the weight-loss version of the same drug.
Mounjaro is a newer medication with a different active ingredient: tirzepatide. Tirzepatide is a dual agonist, meaning it targets two receptors at once: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual action is thought to be why Mounjaro often produces even greater weight loss than semaglutide in clinical trials.
In Canada, Mounjaro is approved for type 2 diabetes. Like Ozempic, it is frequently used off-label for weight loss.
| Feature | Ozempic | Wegovy | Mounjaro |
| Active Ingredient | Semaglutide | Semaglutide | Tirzepatide |
| How It Works | GLP-1 agonist | GLP-1 agonist | GLP-1 + GIP agonist |
| Health Canada Approval | Type 2 diabetes | Weight management | Type 2 diabetes |
| Typical Weight Loss | 5–10% of body weight | 10–15% of body weight | 15–20% of body weight |
| Dosing | Weekly injection | Weekly injection | Weekly injection |
| Common Side Effects | Nausea, vomiting, diarrhea | Nausea, vomiting, diarrhea | Nausea, vomiting, diarrhea |
Clinical trials give us a clear picture of how these medications compare for weight loss.
Because Ozempic and Wegovy are the same drug, the difference in weight loss comes down to dose. Wegovy is approved at higher doses specifically for weight management. In clinical trials, Wegovy helped people lose an average of about 15 percent of their body weight over 68 weeks. Ozempic, used at its diabetes doses, typically produces more modest weight loss, often in the range of 5 to 10 percent.
Head-to-head trials show Mounjaro produces greater weight loss than semaglutide. In the SURMOUNT trials, people taking the highest dose of tirzepatide lost an average of more than 20 percent of their body weight. This makes Mounjaro one of the most powerful weight-loss medications currently available.
There is no single “best” medication. The right choice depends on several factors.
All three medications require a prescription from a doctor. They are available at Canadian pharmacies, including major chains like Shoppers Drug Mart, but availability can vary.
Cost is a major consideration. Without insurance, these medications are expensive, often costing several hundred dollars per month. Coverage depends on your insurance plan and the reason for the prescription. Medications approved for diabetes, like Ozempic and Mounjaro, are more likely to be covered than weight-loss-only medications like Wegovy.
All three medications share a similar side effect profile because they work in similar ways. The most common side effects are gastrointestinal:
These side effects are usually worst when you first start the medication or when your dose increases. They often improve over time. More serious but rare side effects include pancreatitis, gallbladder disease, and a risk of thyroid tumours that has been seen in animal studies.
Discuss your full medical history with your doctor before starting any of these medications.
Ozempic, Wegovy, and Mounjaro are all effective GLP-1-based medications, but they are not interchangeable. Wegovy and Mounjaro generally produce more weight loss, while Ozempic is more commonly covered for diabetes. The right choice depends on your individual health situation, your goals, and your doctor’s recommendation.
If you are considering a GLP-1 medication for weight loss, start by having an honest conversation with your healthcare provider about your options, your insurance coverage, and what you can expect.
This article is for informational purposes only and does not replace professional medical advice. Always consult your physician or a qualified healthcare provider before starting, changing, or stopping any medication or diet plan.
We specialize in Men’s Health.
Themd.ca service is FREE for patients in British Columbia with a valid health number.
For patients located elsewhere in Canada, we provide virtual consultation for men’s health if you are in Alberta, Ontario, New Brunswick, Nova Scotia and Yukon for a flat fee of $40.00. This is changing, so please visit our website for any updates and changes.
Add "Kama Health Pharmacy" on the preferred pharmacy field to lock in affordable medications
